GleamWall
中文EN

TECH BIO-TECHNE Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 842023 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.9%
TTM net income YoY120.5%
TTM EPS YoY124.5%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-11.3%

Margins

Gross margin65.8%
Operating margin19.6%
Net margin14.0%
FCF margin25.1%
EBITDA margin27.5%

Returns

ROE8.3%
ROA6.7%
ROIC (approx.)9.3%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.00x
Current ratio2.28x
Interest coverage27.16x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-6.4%
Payout ratio29.1%
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$299.71M$321.19M$311.42M$295.88M$286.56M$316.96M$316.18M$297.03M
Cost of revenue$103.09M$109.80M$103.13M$104.60M$98.44M$118.15M$101.62M$103.14M
Gross profit$196.62M$211.39M$208.29M$191.28M$188.11M$198.81M$214.56M$193.89M
R&D expense$26.34M$23.95M$23.45M$23.12M$24.24M$26.03M$24.58M$25.02M
SG&A expense$133.68M$113.17M$109.34M$113.69M$116.21M$196.64M$151.27M$121.45M
Operating income$36.60M$74.28M$75.50M$54.46M$47.66M-$23.86M$38.71M$47.42M
Interest expense$2.17M$2.12M$2.40M$2.17M$2.93M$2.18M$2.01M$2.15M
Pretax income$34.69M$70.68M$71.22M$50.78M$47.99M-$22.86M$38.27M$42.88M
Income tax$6.40M$16.06M$20.18M$12.78M$9.81M-$5.18M$15.69M$7.99M
Net income$28.29M$54.62M$51.05M$38.01M$38.19M-$17.68M$22.59M$34.89M
EBITDA$60.33M$98.42M$99.66M$79.17M$72.00M$3.25M$66.28M$74.50M
EPS (basic)0.18—0.330.240.25—0.140.22
EPS (diluted)0.18—0.320.240.24—0.140.22
Dividends declared per share0.080.080.080.080.080.080.080.08
Weighted avg. shares (diluted)157.93M—157.40M157.00M156.36M—158.94M160.63M
Balance sheet
Cash & equivalents$350.04M$264.71M$209.82M$172.88M$144.96M$162.19M$140.67M$177.55M
Short-term investments——————$0$0
Receivables$203.06M$216.59M$214.56M$184.61M$183.90M$206.88M$237.14M$217.94M
Inventory$197.67M$195.74M$201.18M$205.45M$203.19M$189.45M$191.08M$188.37M
Current assets$824.83M$744.40M$688.05M$637.43M$609.51M$608.30M$627.24M$634.64M
PP&E, net$227.76M$231.84M$232.99M$234.38M$240.33M$245.72M$251.98M$249.75M
Goodwill$972.07M$975.36M$977.80M$980.56M$978.91M$980.93M$968.61M$964.61M
Intangibles$287.04M$303.46M$319.07M$334.99M$350.11M$365.60M$443.70M$461.05M
Total assets$2.64B$2.59B$2.55B$2.52B$2.53B$2.56B$2.64B$2.67B
Current liabilities$361.27M$163.70M$153.28M$140.43M$144.54M$175.85M$169.20M$161.26M
Short-term debt$200.00M———————
Long-term debt—$200.00M$200.00M$260.00M$300.00M$346.00M$330.00M$300.00M
Total debt—$200.00M$200.00M$260.00M$300.00M$346.00M$330.00M$300.00M
Total liabilities$471.13M$478.50M$465.30M$511.71M$560.33M$639.06M$626.23M$591.93M
Shareholders' equity$2.17B$2.11B$2.09B$2.01B$1.97B$1.92B$2.02B$2.08B
Net debt—-$64.71M-$9.82M$87.12M$155.04M$183.81M$189.33M$122.45M
Shares outstanding157.05M156.10M156.52M155.88M155.75M154.97M156.76M157.92M
Cash flow statement
Operating cash flow$73.11M$95.42M$86.66M$82.41M$27.59M$98.20M$41.12M$84.35M
Capital expenditure$5.92M$8.48M$9.09M$5.92M$5.36M$4.89M$10.12M$6.82M
Free cash flow$67.20M$86.94M$77.58M$76.49M$22.22M$93.31M$31.00M$77.53M
Investing cash flow-$3.93M-$7.06M-$5.82M-$5.92M$605,000$406,000-$8.87M-$5.03M
Financing cash flow$16.39M-$33.21M-$42.72M-$48.99M-$44.20M-$90.45M-$68.05M-$83.84M
Depreciation & amortization$23.73M$24.14M$24.17M$24.71M$24.34M$27.11M$27.57M$27.08M
Stock-based compensation$13.41M$5.23M$10.49M$13.96M$11.68M$4.55M$11.39M$14.71M
Dividends paid$12.56M$12.48M$12.52M$12.47M$12.44M$12.39M$12.58M$12.74M
Share buybacks—$41.65M$0$0$24,000$100.06M$100.05M—

Free plan shows the latest 8 periods; Pro shows all 69 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.